These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 712064)

  • 41. Participation of T-lymphocytes in the curative effect of a novel synthetic polyamine analogue, N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine, against L1210 leukemia in vivo.
    Bowlin TL; Prakash NJ; Edwards ML; Sjoerdsma A
    Cancer Res; 1991 Jan; 51(1):62-6. PubMed ID: 1988107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Common leukemia-associated antigen of DBA/2 mouse leukemia detected by tumor rejection and complement-dependent cytotoxicity assays.
    Kawashima K; Takeyama H; Takahashi T; Kato Y; Watanabe E; Suzuki H; Minam S; Isobe K; Yamada K; Ito Y
    Gan; 1979 Dec; 70(6):769-76. PubMed ID: 94022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
    Ujiie T
    Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antigen-antibody complexes generate Lyt 1 inducers of suppressor cells.
    Rao VS; Bennett JA; Shen FW; Gershon RK; Mitchell MS
    J Immunol; 1980 Jul; 125(1):63-7. PubMed ID: 6966663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Macrophages as effector cells of protective immunity in murine schistosomiasis. VI. T cell-dependent, lymphokine-mediated, activation of macrophages in response to Schistosoma mansoni antigens.
    James SL; Lazdins JK; Hieny S; Natovitz P
    J Immunol; 1983 Sep; 131(3):1481-6. PubMed ID: 6350456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of effective immunity to Moloney murine sarcoma virus using monoclonal anti-idiotypic antibody as immunogen.
    Powell TJ; Spann R; Nguyenduc M; Lamon EW
    J Immunol; 1989 Feb; 142(4):1318-24. PubMed ID: 2536772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suppression of NK-mediated natural resistance by interferon treatment of murine lymphomas.
    Greenberg AH; Miller V; Jablonski T; Pohajdak B
    J Immunol; 1984 Apr; 132(4):2129-34. PubMed ID: 6199424
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):133-43. PubMed ID: 6265346
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunostimulatory factors specifically associated with a spontaneously regressing tumor subline of the murine leukemia L1210.
    Koo PH
    J Immunol; 1981 Jul; 127(1):373-9. PubMed ID: 7016996
    [No Abstract]   [Full Text] [Related]  

  • 50. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunobiologic studies in hepatoma-bearing mice passively immunized to alpha-fetoprotein.
    Mizejewski GJ; Dillon WR
    Arch Immunol Ther Exp (Warsz); 1979; 27(5):655-62. PubMed ID: 94991
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential effects of preirradiation on adoptive antibody responses in DBA/2 and BALB/c mice.
    Yonkosky D; Buffett RF; Bennett M
    Radiat Res; 1978 Mar; 73(3):521-34. PubMed ID: 305575
    [No Abstract]   [Full Text] [Related]  

  • 53. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
    Kataoka T; Kobayashi H; Sakurai Y
    Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
    [No Abstract]   [Full Text] [Related]  

  • 54. Improved host defense against L1210 leukemia by deprivation of dietary phenylalanine.
    Pine MJ
    Nutr Cancer; 1981; 3(2):94-102. PubMed ID: 7346795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vesicular stomatitis virus-infected L1210 murine leukemia cells: increased immunogenicity and altered surface antigens.
    Wise KS
    J Natl Cancer Inst; 1977 Jan; 58(1):83-90. PubMed ID: 189042
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune rejection mechanisms in murine leukemia. I. Timing of tumor cell rejection process relative to the development of humoral and cell-mediated cytotoxic immune responses.
    Ciavarra RP; Terres G
    Int J Cancer; 1984 Nov; 34(5):681-8. PubMed ID: 6500745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simultaneous development of humoral and cellular tumor-specific immunity against L1210 mouse leukemia.
    Kawashima K; Isobe K; Nagase F; Yokochi T; Nagura E; Hasegawa Y; Morishita H; Yamada K; Nakashima I
    Leuk Res; 1985; 9(7):935-9. PubMed ID: 4021540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia.
    Yi B; Zhang Z; Zhang M; Schwartz-Albiez R; Cao Y
    Oncol Rep; 2013 Oct; 30(4):1841-7. PubMed ID: 23900643
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preparation and therapeutic potential of rabbit antisera with "directed" specificities for mouse leukemias.
    Reif AE; Robinson CM; Smith PJ
    Ann N Y Acad Sci; 1976; 277(00):647-69. PubMed ID: 1069565
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suppression of in vitro primary immune response by L1210 cells and their culture supernatant: evidence for cytotoxic effects.
    Huget RP; Flad HD; Opitz HG
    Cell Immunol; 1977 Mar; 29(1):210-5. PubMed ID: 849606
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.